JADE CURY MARTINS ASFORA LINS

(Fonte: Lattes)
Índice h a partir de 2011
9
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Tipo de produção: article ×

Resultados de Busca

Agora exibindo 1 - 10 de 24
  • article 21 Citação(ões) na Scopus
    Chronic activation profile of circulating CD8+T cells in Sezary syndrome
    (2018) TORREALBA, Marina Passos; MANFRERE, Kelly Cristina; MIYASHIRO, Denis R.; LIMA, Josenilson F.; OLIVEIRA, Luana de M.; PEREIRA, Natalli Z.; CURY-MARTINS, Jade; PEREIRA, Juliana; DUARTE, Alberto J. S.; SATO, Maria N.; SANCHES, Jose A.
    Sezary syndrome (SS) is a leukemic variant of cutaneous T cell lymphoma (CTCL), and the neoplastic CD4+ T cells of SS patients undergo intense clonal proliferation. Although Sezary cells have been studied extensively, studies on adaptive immunity regarding CD8+ T cells are scarce. This study aimed to investigate activation marker expression in CD8+ T cells according to the differentiation stages and IL-7/IL7Ra axis responses of patients with SS. Moreover, this study aimed to verify the soluble forms of CD38, sCD127 and IL-7 in serum. Although the SS patients of our cohort had reduced numbers of CD8+ T cells, they exhibited higher percentages of CD8+CD38+T cells, mainly effector/memory CD8+ T cells, than the control group. In contrast, down-regulated expression of the activation markers CD127/IL-7R and CD26 was found in the CD8+ T cells of SS patients. High serum levels of sCD38 and sCD127 and scarce serum levels of IL-7 were detected, emphasizing the immune activation status of SS patients. Moreover, CD8+ T cells from SS patients exhibited IL-7 unresponsiveness to STAT5 phosphorylation and Bcl-2 expression, and IL-7 priming partially restored IFN gamma production. Our findings showed a chronic activation profile of CD8+ T cells, as an attenuated cytotoxic profile and impaired IL-7 responsiveness was observed, suggesting chronic activation status of CD8+ T cells in SS patients.
  • article 0 Citação(ões) na Scopus
    Image-guided lymph node core needle biopsy in mycosis fungoides/Sezary syndrome: Direct comparison to surgical excision
    (2022) CURY-MARTINS, Jade; COUTO NETTO, Sergio Dias do; CASTRO, Stephanie Catarine Carqueijo de; SIQUEIRA, Sheila Aparecida Coelho; GIANNOTTI, Marcelo Abrantes; ZERBINI, Maria Claudia Nogueira; PEREIRA, Juliana; CULLER, Hebert; TEIXEIRA JR., Frederico Jose Ribeiro; MENEZES, Marcos Roberto de; SANCHES, Jose Antonio
  • article 5 Citação(ões) na Scopus
    Extra-acral cutaneous sclerosing perineurioma with CD34 fingerprint pattern
    (2017) MACARENCO, Ricardo S.; CURY-MARTINS, Jade
    Sclerosing perineuroma is a variant of extraneural perineurioma that, as a rule, occurs in acral sites. However, it has also been occasionally reported in non-acral regions. Recently, CD34 expression in a pattern reminiscent of the human fingerprint has been observed in a subset of perineuriomas, but this immunohistochemical finding has not been documented in non-acral sclerosing perineuriomas. We report a case of sclerosing perineurioma presenting CD34 expression in a fingerprint-like pattern on the skin of the neck (a previously unreported site for this neoplasm) of a 56-year-old man. In addition, alpha smooth-muscle actin showed a similar pattern of expression, suggesting that the cell population implicated in the remarkable immunolabeling is most probably fibroblastic/myofibroblastic. Other immunohistochemical findings included epithelial membrane antigen and claudin1positive lesional cells, and the absence of S100, glucose transporter protein 1, MUC4 and desmin.
  • article 21 Citação(ões) na Scopus
    Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
    (2020) CURY-MARTINS, Jade; ERIS, Adriana Pessoa Mendes; ABDALLA, Cristina Martinez Zugaib; SILVA, Giselle de Barros; MOURA, Veronica Paula Torel de; SANCHES, Jose Antonio
    With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences. (C) 2020 Sociedade Brasileira de Dermatologia.
  • article 6 Citação(ões) na Scopus
    Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sezary syndrome
    (2017) MANFRERE, Kelly C. G.; TORREALBA, Marina P.; MIYASHIRO, Denis R.; PEREIRA, Natalli Z.; YOSHIKAWA, Fabio S. Y.; OLIVEIRA, Luana de M.; CURY-MARTINS, Jade; DUARTE, Alberto J. S.; SANCHES, Jose A.; SATO, Maria N.
    Sezary syndrome (SS), an aggressive and leukemic form of cutaneous T-cell lymphoma, usually results in shortened survival. Improving innate immunity in SS by targeting natural killer (NK) cells with Toll-like receptor (TLR) agonists could be an interesting modulatory strategy. We evaluated the NK cell populations in SS patients assessing activating and inhibitory receptors expression and profiled the differential expression of TLR signaling pathway genes in unstimulated NK cells and after TLR7/8 stimulation. We observed preserved CD56(bright) NK cells and a low percentage of CD56(dim) NK cells in the peripheral blood of SS patients compared to those in the healthy control group. Both NK cell populations showed down-modulation of NKG2C and NKG2D expression, which was associated with high serum levels of the soluble form of NKG2D ligands. In contrast, an expansion of ""memory"" CD57+ NKG2C+ NK cells and high cytomegalovirus antibody titers were detected in SS patients. Profiling of the TLR signaling genes in NK cells from SS patients showed an abundance of differentially expressed genes (DEGs) in NK cells in the unstimulated condition, with mostly up-regulation of NF kappa B/JNK p38 pathway genes, but there was down-regulation of type I (IFN-alpha/beta) and II (IFN-gamma) interferon and IL-12A. After activation of NK cells with TLR7/8 agonist, the down-regulated genes correlated with the IFN response, and IL-12 became up-regulated, together with other antitumor factors. NK cell activation with a dual agonist for TLR7 and TLR8 is able to induce the expression of IFN-gamma and type I IFN, which can improve immunity in SS patients.
  • article 15 Citação(ões) na Scopus
    Dermoscopy of primary cutaneous B- and T-cell lymphomas and pseudolymphomas presenting as solitary nodules and tumors: a case-control study with histopathologic correlation
    (2019) NAVARRETE-DECHENT, Cristian; PUERTO, Constanza del; ABARZUA-ARAYA, Alvaro; MOLGO, Montserrat; GELLER, Shamir; ANDREANI, Sebastian; CURY-MARTINS, Jade; SANCHES, Jose A.; MONTOYA, Javier; GONZALEZ, Sergio; URIBE, Pablo
    Background Primary cutaneous lymphomas (PCLs) and pseudolymphomas presenting as single pink-red nodules/tumors are highly unspecific and include a wide differential diagnosis. Objective To describe the dermoscopic characteristics of PCL/pseudolymphoma. Methods In this retrospective, case-control study, we evaluated the dermoscopic features of patients with solitary PCL/pseudolymphoma tumors and compared them to a control group of non-lymphomatous, nonpigmented, solitary tumors (e.g., basal cell carcinoma, amelanotic melanoma, etc). Results We included 14 patients with PCL/pseudolymphomas and 35 controls. T-cell and B-cell lymphoma proportions were 28.6% (n = 4) and 71.4% (n = 10), respectively. Compared to controls, most lymphomas presented dermoscopically with orange color (71.4% vs. 14.2%, P < 0.001), follicular plugs (85% vs. 2.8%, P < 0.001), and as organized lesions (85% vs. 31.4%, P = 0.001). Coexistence of orange color and follicular plugs had an odds ratio (OR) of 2.8 (P < 0.001), highly suggestive of PCL . The kappa index for independent observers was 0.66, 0.49, 0.43 for orange background, follicular plugs, and organized lesion, respectively. Histopathologic correlation was performed in six PCL cases and showed dense diffuse and perifollicular lymphocytic infiltrate in all cases and keratin plugs in five of six cases, possibly correlating with the orange color and the follicular plugs, respectively. Conclusion Primary cutaneous lymphomas/pseudolymphomas present with characteristic dermoscopic findings irrespective of immunohistochemical subtype.
  • article 310 Citação(ões) na Scopus
    Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
    (2015) SCARISBRICK, Julia J.; PRINCE, H. Miles; VERMEER, Maarten H.; QUAGLINO, Pietro; HORWITZ, Steven; PORCU, Pierluigi; STADLER, Rudolf; WOOD, Gary S.; BEYLOT-BARRY, Marie; PHAM-LEDARD, Anne; FOSS, Francine; GIRARDI, Michael; BAGOT, Martine; MICHEL, Laurence; BATTISTELLA, Maxime; GUITART, Joan; KUZEL, Timothy M.; MARTINEZ-ESCALA, Maria Estela; ESTRACH, Teresa; PAPADAVID, Evangelia; ANTONIOU, Christina; RIGOPOULOS, Dimitis; NIKOLAOU, Vassilki; SUGAYA, Makoto; MIYAGAKI, Tomomitsu; GNIADECKI, Robert; SANCHES, Jose Antonio; CURY-MARTINS, Jade; MIYASHIRO, Denis; SERVITJE, Octavio; MUNIESA, Cristina; BERTI, Emilio; ONIDA, Francesco; CORTI, Laura; HODAK, Emilia; AMITAY-LAISH, Iris; ORTIZ-ROMERO, Pablo L.; RODRIGUEZ-PERALTO, Jose L.; KNOBLER, Robert; PORKERT, Stefanie; BAUER, Wolfgang; PIMPINELLI, Nicola; GRANDI, Vieri; COWAN, Richard; ROOK, Alain; KIM, Ellen; PILERI, Alessandro; PATRIZI, Annalisa; PUJOL, Ramon M.; WONG, Henry; TYLER, Kelly; STRANZENBACH, Rene; QUERFELD, Christiane; FAVA, Paolo; MAULE, Milena; WILLEMZE, Rein; EVISON, Felicity; MORRIS, Stephen; TWIGGER, Robert; TALPUR, Rakhshandra; KIM, Jinah; OGNIBENE, Grant; LI, Shufeng; TAVALLAEE, Mahkam; HOPPE, Richard T.; DUVIC, Madeleine; WHITTAKER, Sean J.; KIM, Youn H.
    Purpose Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients. (C) 2015 by American Society of Clinical Oncology
  • article 22 Citação(ões) na Scopus
    Progression of mycosis fungoides after treatment with dupilumab: A case report
    (2020) MIYASHIRO, Denis; VIVARELLI, Ana Gabriela; GONCALVES, Fernanda; CURY-MARTINS, Jade; SANCHES, Jose Antonio
  • article 7 Citação(ões) na Scopus
    Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
    (2022) CEGLIO, William Queiroz Guimaraes Wiegandt; REBEIS, Marina Mattos; SANTANA, Marcela Ferreira; MIYASHIRO, Denis; CURY-MARTINS, Jade; SANCHES, Jose Antonio
    Background: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen. Objective: To evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment. Methods: A retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital. Results: A total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. Study limitations: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events. Conclusion: A wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens. (C) 2021 Sociedade Brasileira de Dermatologia.
  • article 1 Citação(ões) na Scopus
    Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey
    (2023) QUAGLINO, Pietro; SCARISBRICK, Julia; ROCCUZZO, Gabriele; ABELDANO, Alejandra; BATTISTELLA, Maxime; MCCORMACK, Chris; COWAN, Richard; COZZIO, Antonio; CURY-MARTINS, Jade; ENZ, Paula; GESKIN, Larisa; GUENOVA, Emmanuella; KIM, Youn H.; KNOBLER, Robert; LITVINOV, Ivan V.; MIYAGAKI, Tomomitsu; MOLGO, Montserrat; NICOLAY, Jan; PAPADAVID, Evangelina; PINTER-BROWN, Lauren; VALLVERDU, Ramon Pujol; QUERFELD, Christiane; ORTIZ-ROMERO, Pablo; STADLER, Rudolf; VERMEER, Maarten H.; BAGOT, Martine; HODAK, Emmilia
    Background Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking. ObjectivesTo delineate a comprehensive view on how the 'plaque' entity is defined and managed in clinical practice; to evaluate whether the current positioning of plaques in the TNMB classification is adequate. MethodsA 12-item survey was circulated within a selected panel of 22 experts (pathologists, dermatologists, haematologists and oncologists), members of the EORTC and International Society for Cutaneous Lymphoma. The questionnaire discussed clinical and histopathological definitions of plaques and its relationship with staging and treatment. Results Total consensus and very high agreement rates were reached in 33.3% of questions, as all panellists regularly check for the presence of plaques, agree to evaluate the presence of plaques as a potential separate T class, and concur on the important distinction between plaque and patch for the management of early-stage MF. High agreement was reached in 41.7% of questions, since more than 50% of the responders use Olsen's definition of plaque, recommend the distinction between thin/thick plaques, and agree on performing a biopsy on the most infiltrated/indurated lesion. High divergence rates (25%) were reported regarding the possibility of a clinically based distinction between thin and thick plaques and the role of histopathology to plaque definition. ConclusionsThe definition of 'plaque' is commonly perceived as a clinical entity and its integration with histopathological features is generally reserved to specific cases. To date, no consensus is achieved as for the exact definition of thin and thick plaques and current positioning of plaques within the TNMB system is considered clinically inadequate. Prospective studies evaluating the role of histopathological parameters and other biomarkers, as well as promising diagnostic tools, such as US/RM imaging and high-throughput blood sequencing, are much needed to fully integrate current clinical definitions with more objective parameters.